You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 12,144,801

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,144,801

Title:	Methods and compositions for treatment of epileptic disorders
Abstract:	Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Inventor(s):	Matthew During
Assignee:	Ovid Therapeutics Inc
Application Number:	US17/863,902
Patent Claims:	1. A method of treating seizures associated with CDKL5 deficiency disorder, comprising administering to a subject in need thereof a therapeutically effective amount of pharmaceutical composition comprising ganaxolone, wherein the therapeutically effective amount is administered three times per day. 2. The method of claim 1, wherein ganaxolone is administered orally. 3. The method of claim 1, wherein ganaxolone is administered as a tablet. 4. The method of claim 1, wherein ganaxolone is administered as a capsule. 5. The method of claim 1, wherein the pharmaceutical composition is a liquid composition and comprises about 50 mg/ml of ganaxolone. 6. The method of claim 1, wherein the therapeutically effective amount is up to 1800 mg per day. 7. The method of claim 6, wherein the therapeutically effective amount is administered as about 600 mg three times per day. 8. The method of claim 1, wherein the therapeutically effective amount is up to 1350 mg per day. 9. The method of claim 8, wherein the therapeutically effective amount is administered as about 450 mg three times per day. 10. The method of claim 1, wherein the therapeutically effective amount is up to 900 mg per day. 11. The method of claim 10, wherein the therapeutically effective amount is administered as about 300 mg three times per day. 12. The method of claim 1, wherein the therapeutically effective amount is up to 450 mg per day. 13. The method of claim 12, wherein the therapeutically effective amount is administered as about 150 mg three times per day. 14. The method of claim 1, wherein the therapeutically effective amount is administered as up to about 21 mg/kg three times per day. 15. The method of claim 1, wherein the therapeutically effective amount is administered as up to about 16 mg/kg three times per day. 16. The method of claim 1, wherein the therapeutically effective amount is administered as up to about 6 mg/kg three times per day. 17. The method of claim 1, wherein the frequency of seizures is reduced. 18. The method of claim 1, wherein the frequency of seizures is reduced, the severity of seizures is reduced, or a combination thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.